[go: up one dir, main page]

ECSP12012314A - Factor viii conjugado para coagulación de la sangre - Google Patents

Factor viii conjugado para coagulación de la sangre

Info

Publication number
ECSP12012314A
ECSP12012314A ECSP12012314A ECSP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A
Authority
EC
Ecuador
Prior art keywords
factor viii
blood coagulation
fviii
conjugated factor
conjugated
Prior art date
Application number
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of ECSP12012314A publication Critical patent/ECSP12012314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un polímero biocompatible conjugado a FVIII por medio de uno o más residuos de cisteína, adecuadamente por medio de un enlazador a través de un enlace disulfuro reducido en FVIII, y composiciones farmacéuticas que comprenden esas formas conjugadas de FVIII.
ECSP12012314 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre ECSP12012314A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
ECSP12012314A true ECSP12012314A (es) 2013-05-31

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012314 ECSP12012314A (es) 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre

Country Status (26)

Country Link
US (1) US20130150302A1 (es)
EP (1) EP2563402A1 (es)
JP (1) JP5870088B2 (es)
KR (1) KR20130055619A (es)
CN (1) CN102939108A (es)
AP (1) AP2012006575A0 (es)
AU (1) AU2011247147B2 (es)
BR (1) BR112012027590A2 (es)
CA (1) CA2797058A1 (es)
CL (1) CL2012003039A1 (es)
CO (1) CO6660443A2 (es)
CR (1) CR20120579A (es)
EA (1) EA201290938A1 (es)
EC (1) ECSP12012314A (es)
GB (2) GB201007357D0 (es)
IL (1) IL222566A (es)
MX (1) MX2012012683A (es)
MY (1) MY160922A (es)
NI (1) NI201200160A (es)
NZ (1) NZ603939A (es)
PE (1) PE20130254A1 (es)
PH (1) PH12012502150A1 (es)
RU (1) RU2012144555A (es)
SG (1) SG184906A1 (es)
WO (1) WO2011135307A1 (es)
ZA (1) ZA201208989B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
EP3816181A4 (en) 2018-05-18 2022-04-20 Zhengzhou Gensciences Inc. Improved fviii fusion protein and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058897T2 (hu) * 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2821832T3 (es) * 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP1835938B1 (en) * 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
WO2009047500A1 (en) 2007-10-09 2009-04-16 Polytherics Limited Novel conjugated proteins and peptides
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
DK2326349T3 (en) * 2008-07-21 2015-05-26 Polytherics Ltd Novel Reagents and Methods for Conjugation of Biological Molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
NI201200160A (es) 2013-04-19
CO6660443A2 (es) 2013-04-30
JP2013525414A (ja) 2013-06-20
RU2012144555A (ru) 2014-06-10
US20130150302A1 (en) 2013-06-13
KR20130055619A (ko) 2013-05-28
NZ603939A (en) 2013-08-30
AU2011247147B2 (en) 2014-09-18
PH12012502150A1 (en) 2013-02-04
GB2492935B8 (en) 2014-10-29
GB201007357D0 (en) 2010-06-16
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
AP2012006575A0 (en) 2012-12-31
CN102939108A (zh) 2013-02-20
MX2012012683A (es) 2013-04-03
CA2797058A1 (en) 2011-11-03
BR112012027590A2 (pt) 2016-08-09
GB2492935B (en) 2014-04-30
WO2011135307A1 (en) 2011-11-03
CL2012003039A1 (es) 2014-01-24
IL222566A0 (en) 2012-12-31
GB201220667D0 (en) 2013-01-02
GB2492935A (en) 2013-01-16
CR20120579A (es) 2013-04-25
EP2563402A1 (en) 2013-03-06
HK1173946A1 (en) 2013-05-31
IL222566A (en) 2017-12-31
GB2492935A8 (en) 2014-10-29
PE20130254A1 (es) 2013-03-16
ZA201208989B (en) 2014-02-26
JP5870088B2 (ja) 2016-02-24
MY160922A (en) 2017-03-31
SG184906A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
ECSP12012314A (es) Factor viii conjugado para coagulación de la sangre
ECSP12012315A (es) FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE
BR112012017488A2 (pt) "dispositivo"
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
CY1118680T1 (el) Φαρμακευτικη συνθεση
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
BR112012020790A2 (pt) anticorpo de neutralização da integrina alfavbeta8
EP2830521A4 (en) GLENOID IMPLANT SURGERY USING PATIENT SPECIFIC INSTRUMENTS
GT201300208A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MX2013003365A (es) Composicion farmaceutica.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
UY37922A (es) Composiciones farmacéuticas que comprenden un profármaco deadrenomedulina basado en polietilenglicol
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BR112012029304A2 (pt) copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b